Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Dr. Weng holds an M.D. from the Tongji Medical University, and an M.A. in Health Planning, Policy and Management from the University of Leeds. SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the "Board") effective August 18, 2025. Dr. Wen ...